Phase I trial of hypofractionated chemoradiotherapy in the palliative management of esophageal and gastro-esophageal cancer
Swetha Sridha, Jarad Martin(Calvary Mater Newcastle Hospital), Brandan Holt(Calvary Mater Newcastle Hospital), James Lynam, Jasmin Loh(University Malaya Medical Centre), Mahesh Kumar(Calvary Mater Newcastle Hospital), Anthony Bonaventura(Calvary Mater Newcastle Hospital), Hiren Mandaliya(Lake Macquarie Private Hospital), Joanne Smart, Fiona Day(Calvary Mater Newcastle Hospital)
Cited by 0
Related Papers
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI)
|Translational Lung Cancer Research|2019|392
Food protein–induced enterocolitis syndrome in Australia: A population-based study, 2012-2014
|Journal of Allergy and Clinical Immunology|2017|200
Hematopoietic stem cell transplantation for CD40 ligand deficiency: Results from an EBMT/ESID-IEWP-SCETIDE-PIDTC study
|Journal of Allergy and Clinical Immunology|2019|91